Cargando…

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections

Antimicrobial resistance has become one of the greatest threats to public health, with rising resistance to carbapenems being a particular concern due to the lack of effective and safe alternative treatment options. Carbapenem-resistant gram-negative bacteria of clinical relevance include the Entero...

Descripción completa

Detalles Bibliográficos
Autor principal:	Doi, Yohei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853760/ https://www.ncbi.nlm.nih.gov/pubmed/31724043 http://dx.doi.org/10.1093/cid/ciz830

Ejemplares similares

The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections
por: Bouza, Emilio
Publicado: (2021)

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
por: Nordmann, Patrice, et al.
Publicado: (2019)

Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
por: Lee, Chang-Seop, et al.
Publicado: (2014)

Molecular epidemiology & therapeutic options of carbapenem-resistant Gram-negative bacteria
por: Garg, Atul, et al.
Publicado: (2019)

Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections
por: Bassetti, Matteo, et al.
Publicado: (2021)

Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections
por: Shields, Ryan K, et al.
Publicado: (2023)

Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
por: Falcone, Marco
Publicado: (2021)

Drug Repurposing of the Unithiol: Inhibition of Metallo-β-Lactamases for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections
por: Grigorenko, Vitaly G., et al.
Publicado: (2022)

Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort
por: Bezerra, Camila L P A M, et al.
Publicado: (2023)

Temocillin use as a carbapenem-sparing option in a UK teaching hospital for treating serious Gram-negative bacterial infections
por: Enoch, D A, et al.
Publicado: (2022)

Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis
por: Li, Yuan-yuan, et al.
Publicado: (2020)

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections
por: Chopra, Teena
Publicado: (2021)

Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
por: Morrill, Haley J., et al.
Publicado: (2015)

Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
por: Jean, Shio-Shin, et al.
Publicado: (2022)

1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study
por: Bassetti, Matteo, et al.
Publicado: (2020)

Predictors of Mortality in Patients with Infections Due to Carbapenem-Resistant Gram-Negative Bacteria
por: Rivera-Villegas, Hector Orlando, et al.
Publicado: (2023)

Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Carbapenem-Resistant Gram-Negative Bacterial Infections Among Chinese Children
por: Jia, Xuedong, et al.
Publicado: (2022)

Investigation and analysis of carbapenem-resistant gram-negative bacterial infection rates across hospitals in Shandong Province in China
por: Liu, Keke, et al.
Publicado: (2022)

Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria
por: Lu, Jiayue, et al.
Publicado: (2022)

Gram-negative infections: evolving treatments with expanding options
por: Villegas, Maria Virginia, et al.
Publicado: (2018)

Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection
por: Xiao, Shuang, et al.
Publicado: (2023)

Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections
por: Xia, G. L., et al.
Publicado: (2021)

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections
por: Gavaghan, Victoria, et al.
Publicado: (2022)

Clinical efficacy and nephrotoxicity of intravenous colistin sulfate in the treatment of carbapenem-resistant gram-negative bacterial infections: a retrospective cohort study
por: Jin, Jun, et al.
Publicado: (2022)

Comparison of Risk Factors and Outcomes in Carbapenem-Resistant and Carbapenem-Susceptible Gram-Negative Bacteremia
por: Cetin, Sinan, et al.
Publicado: (2021)

Carbapenem-resistant gram-negative bacterial infection in intensive care unit patients: Antibiotic resistance analysis and predictive model development
por: Liao, Qiuxia, et al.
Publicado: (2023)

Optimizing the use of carbapenems in the face of increasing Gram-negative resistance
por: Ramphal, Reuben
Publicado: (2008)

Editorial: The global threat of carbapenem-resistant gram-negative bacteria
por: Dropa, Milena, et al.
Publicado: (2022)

Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study
por: Zhang, Xiaojuan, et al.
Publicado: (2021)

Polymyxin B-Associated Nephrotoxicity and Its Predictors: A Retrospective Study in Carbapenem-Resistant Gram-Negative Bacterial Infections
por: Wu, Xiao-Li, et al.
Publicado: (2022)

A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options
por: Elshamy, Ann A, et al.
Publicado: (2020)

Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study
por: Cai, Yiying, et al.
Publicado: (2020)

The role of carbapenems in initial therapy for serious Gram-negative infections
por: Rahal, James J
Publicado: (2008)

Carbapenem-resistant Enterobacteriaceae (CRE) and gram-negative bacterial infections in south-west Nigeria: a retrospective epidemiological surveillance study
por: Adesanya, Oluwafolajimi Adetoye, et al.
Publicado: (2020)

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
por: Alosaimy, Sara, et al.
Publicado: (2021)

Using Molecular Diagnostics to Develop Therapeutic Strategies for Carbapenem-Resistant Gram-Negative Infections
por: Tenover, Fred C.
Publicado: (2021)

Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens
por: Cruz-López, Flora, et al.
Publicado: (2022)

Calculated parenteral initial treatment of bacterial infections: Infections with multi-resistant Gram-negative rods – ESBL producers, carbapenemase-producing Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii
por: Grabein, Béatrice, et al.
Publicado: (2020)

Drug Resistance and Molecular Epidemiology of Carbapenem Resistant Gram-negative Bacilli Isolates
por: Naim, Huma, et al.
Publicado: (2018)

Risk Factors for Development of Carbapenem Resistance Among Gram-Negative Rods
por: Richter, Stefan E, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5asn5nkhtashp6vhjuhfl16e1i